Research programme: anti-EGFR therapeutics - PharmexaAlternative Names: EGFR AutoVac
Latest Information Update: 05 Sep 2007
At a glance
- Originator Pharmexa
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 05 Sep 2007 Discontinued - Preclinical for Cancer in Denmark (unspecified route)
- 11 Jan 2005 Pharmexa and Epimmune have expanded their non-exclusive licence agreement of 2001 to include additional target antigens
- 09 Jul 2004 Preclinical trials in Cancer in Denmark (unspecified route)